Qrativ combines nference’s AI-driven knowledge synthesis platform with Mayo Clinic’s medical expertise and clinical data to enable systematic drug purposing. Its Darwin.ai platform triangulates neural‑network–derived signals from the biomedical literature with real‑world phenotypic and molecular patient evidence. The company’s initial focus is on rare diseases and highly targeted patient populations to identify potential indications and responder subgroups early in development. Qrativ’s management team includes Murali Aravamudan (CEO), Andrew Badley (co‑founder and CMO), Venky Soundararajan (co‑founder and CSO) and Agustin Lopez Marquez (VP, Business Development and Marketing). Mayo Clinic and Dr. Andrew Badley have a financial interest in Qrativ; Mayo Clinic will use any revenue it receives to support its not‑for‑profit mission. The launch was announced from Cambridge, Mass. and Rochester, Minn.

Total raised

$8M

Funding rounds

1

Latest round

Series A

Latest activity

Jul 2017